Turning Pharmaceuticals CEO Martin Shkreli defended raising the price of Daraprim from $13.50 to $750, even though it is used to treat vulnerable groups like AIDS and cancer patients. “The drug was unprofitable at the former price...
CBS reporter grills pharmaceutical CEO: ‘You see how greedy this move looks’
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться